ALIBABA-CLOUD
3.11.2022 03:46:36 CET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, started its annual Apsara Conference today by announcing the launch of ModelScope, an open-source Model-as-a-Service (MaaS) platform that comes with hundreds of AI models, including large pre-trained models for global developers and researchers. During its flagship conference, the global leading cloud provider also introduced a range of serverless database products and upgraded its integrated data analytics and intelligent computing platform to help customers further achieve business innovation through cloud technologies.
"Cloud computing has given rise to a fundamental revolution in the way computing resources are organized, produced and put to commercial use while shifting the paradigm of software development and speeding up the integration of the cloud and endpoint terminals," Jeff Zhang, President of Alibaba Cloud Intelligence, "As more customers are speeding up with their cloud adoption, we have been upgrading our cloud-based resources, services and tools to become serverless, more intelligent and digitalized in order to lower the barrier for companies to adopt new technology and capture more opportunities in the cloud era."
MaaS to create transparent and inclusive technology community
The ModelScope platform is today launched with over 300 ready-to-deploy AI models developed by Alibaba DAMO Academy ("DAMO"), Alibaba's global research initiative, in the past five years. These models cover various fields from computer vision to natural language processing (NLP) and audio. The platform also includes more than 150 state-of-the-art (SOTA) models, which are recognized globally as the best in their respective fields for achieving the results in a given task.
Also made available on the platform are Alibaba’s proprietary large pre-trained models such as Tongyi, which is capable of turning text into image with five billion parameters, and OFA (One-For-All), a six billion-parameter pre-trained model that excels at cross-modal tasks such as image captioning and visual question answering. Independent developers have also contributed dozens of models to the open-source platform to date.
As an open-source community, ModelScope aims to make developing and running AI models easier and more cost effective. Developers and researchers can simply test the models online for free and get the results of their tests within minutes. They can also develop customized AI application by fine-tuning existing models, and run the models online backed by Alibaba Cloud, or deploy them on other cloud platforms or in a local setting.
The launch underscores DAMO’s ongoing efforts and commitment to promote transparent and inclusive technology by reducing the threshold for building and running AI models, enabling universities and smaller companies to easily use AI for their research and in their business respectively. The community is expected to grow further with more quality models available on the platform from DAMO, partners from research institutes and third-party developers in the near future.
New and upgraded solutions to increase computing efficiency
Staying ahead of the emerging trend of serverless software development, Alibaba Cloud is making its key cloud products serverless to enable customers to concentrate on product deployment and development without worrying about managing servers and infrastructure. Essentially, Alibaba Cloud’s updated products focus on turning computing power into an on-demand capability for users.
Examples of these are the cloud native database PolarDB, the cloud-native data warehouse AnalyticDB (ADB) and ApsaraDB for Relational Database Service (RDS). Leveraging Alibaba Cloud’s serverless technologies, customers can enjoy automatic scaling with extreme elasticity based on actual workloads and a pay-as-you-go billing model to reduce costs. The automatic elastic scaling time on demands can be as little as one second. The use of updated database products can help businesses in the internet industry reduce their costs by 50%, on average, compared to using traditional ones. Currently, Alibaba Cloud has more than 20 serverless key products in total and is adding more product categories to become serverless.
Alibaba Cloud also upgraded its ODPS (Open Data Platform and Services), a self-developed integrated data analytics and intelligent computing platform, to provide companies with diversified data processing and analytics services. The platform can handle both online and offline data simultaneously in one system, providing businesses dealing with complex workloads with analytics for business decision-making with reduced cost and increased efficiency.
ODPS has refreshed global records for big data performance, according to recent results from the Transaction Processing Performance Council (TPC), an industry council that sets the standards for transaction processing and database benchmarking. Evaluated based on a 100 TB data benchmark, the performance of ODPS Maxcompute Cluster attained the top score for the sixth consecutive year. ODPS Hologres Cluster also shown a record-breaking result in the TPC-H 30000GB decision support benchmark test.
To drive workload collaboration between cloud and local hardware, Alibaba Cloud has announced the launch of the Wuying Architecture with a showcase on its applications on the Wuying Cloudbook. The Cloudbook with dedicated Architecture is designed to help users access unlimited computing power on the cloud in a more secure and agile manner while supporting collaboration and flexibility at a workplace.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom